Cargando…
Multisystem immune-related adverse events due to toripalimab: Two cases-based review
Immune checkpoint inhibitors (ICIs) have significantly improved the survival of patients with advanced tumors. However, immune-related adverse events (irAEs) caused by ICIs, especially high-grade irAEs, are of growing concern. High-grade multisystem irAEs due to toripalimab, a programmed cell death-...
Autores principales: | Chen, Yanran, Chen, Yulan, Xie, Jingyi, Liu, Dongzhou, Hong, Xiaoping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732722/ https://www.ncbi.nlm.nih.gov/pubmed/36505392 http://dx.doi.org/10.3389/fcvm.2022.1036603 |
Ejemplares similares
-
Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment
por: Luo, Yue-Bei, et al.
Publicado: (2021) -
MELD-XI Score Is Associated With Short-Term Adverse Events in Patients With Heart Failure With Preserved Ejection
por: Wang, Sunying, et al.
Publicado: (2021) -
Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
por: Tao, Ye, et al.
Publicado: (2023) -
Corrigendum: MELD-XI Score Is Associated With Short-Term Adverse Events in Patients With Heart Failure With Preserved Ejection
por: Wang, Sunying, et al.
Publicado: (2021) -
Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022
por: Wu, Si, et al.
Publicado: (2022)